New hope for rare immune diseases: targeted drug trial launches
NCT ID NCT06153173
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 30 times
Summary
This study tests a drug called mirdametinib in people aged 2 and older with certain rare immune cell diseases (like Langerhans cell histiocytosis). The goal is to see if it works better and causes fewer side effects than current treatments. About 40 participants will take the drug for up to a year, and doctors will measure how well tumors shrink using scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.